{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T21:43:55Z","timestamp":1792446235241,"version":"4.5.0"},"reference-count":45,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,7]]},"abstract":"<jats:p>Postfinasteride syndrome (PFS) is a term coined to characterize a constellation of reported undesirable sexual, physical, and neuropsychiatric side effects. In the present study, we conducted the meta-analysis to demonstrate whether the use of 5\u03b1-reductase inhibitors (5ARIs) increases the risk of PFS-like adverse effects. A search of studies published until May 10, 2020, was performed using PubMed, EMBASE, and the Cochrane Library. We included randomized controlled trials with at least one comparison between male patients receiving 5ARIs versus placebo for the treatment of benign prostatic hyperplasia (BPH) or androgenetic alopecia (AGA), and identified 34 studies from 28 articles that met our eligibility criteria. In the random-effects model, the overall use of 5ARIs exhibited a 1.87-fold risk of PFS-like adverse effects during the trial (95% confidence interval [CI]: 1.64\u20132.14). Regarding specific types of adverse effects, the use of 5ARIs had a 1.89-fold risk of sexual adverse effects (95% CI: 1.74\u20132.05) and was associated with an increased risk of physical adverse effects (relative risk [RR]: 1.31, 95% CI: 0.80\u20132.15), albeit without statistical significance. This meta-analysis helped to better define the adverse effects caused by 5ARIs. We concluded that the overall use of 5ARIs significantly increased the risk of PFS-like adverse effects in men with AGA or BPH during treatment. Enhanced awareness of and education on the PFS-like adverse effects are necessary for clinicians.<\/jats:p>","DOI":"10.4103\/aja202171","type":"journal-article","created":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:49:34Z","timestamp":1635727774000},"page":"390-397","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":12,"title":["Sexual, physical, and overall adverse effects in patients treated with 5\u03b1-reductase inhibitors: a systematic review and meta-analysis"],"prefix":"10.4103","volume":"24","author":[{"given":"Jun-Jie","family":"Zhang","sequence":"first","affiliation":[{"name":"Department of Urology, The Third Xiangya Hospital, Central South University, Changsha 410008, China"},{"name":"Department of Urology, Xiangya Hospital, Central South University, Changsha 410013, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao","family":"Shi","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, The Third Xiangya Hospital, Central South University, Changsha 410013, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ting","family":"Wu","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, The Third Xiangya Hospital, Central South University, Changsha 410013, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meng-Da","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Urology, The Third Xiangya Hospital, Central South University, Changsha 410008, China"},{"name":"Department of Urology, Xiangya Hospital, Central South University, Changsha 410013, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin","family":"Tang","sequence":"additional","affiliation":[{"name":"Department of Urology, The Third Xiangya Hospital, Central South University, Changsha 410008, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guang-Ming","family":"Yin","sequence":"additional","affiliation":[{"name":"Department of Urology, The Third Xiangya Hospital, Central South University, Changsha 410008, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhi","family":"Long","sequence":"additional","affiliation":[{"name":"Department of Urology, The Third Xiangya Hospital, Central South University, Changsha 410008, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Le-Ye","family":"He","sequence":"additional","affiliation":[{"name":"Department of Urology, The Third Xiangya Hospital, Central South University, Changsha 410008, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin","family":"Qi","sequence":"additional","affiliation":[{"name":"Department of Urology, Xiangya Hospital, Central South University, Changsha 410013, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Long","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Urology, The Third Xiangya Hospital, Central South University, Changsha 410008, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2021,10,29]]},"reference":[{"key":"-20240829","doi-asserted-by":"crossref","first-page":"l5047","DOI":"10.1136\/bmj.l5047","article-title":"Post-finasteride syndrome","volume":"366","author":"Gray","year":"2019","journal-title":"BMJ"},{"key":"-20240829","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1111\/bjd.16658","article-title":"\u2018Post-finasteride syndrome\u2019: what to tell our female patients?","volume":"179","author":"Mervis","year":"2018","journal-title":"Br J Dermatol"},{"key":"-20240829","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.abd.2020.02.001","article-title":"Post-finasteride syndrome","volume":"95","author":"Pereira","year":"2020","journal-title":"An Bras Dermatol"},{"key":"-20240829","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.fertnstert.2019.11.030","article-title":"Post-finasteride syndrome: a surmountable challenge for clinicians","volume":"113","author":"Traish","year":"2020","journal-title":"Fertil Steril"},{"key":"-20240829","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/2046-4053-4-1","article-title":"Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement","volume":"4","author":"Moher","year":"2015","journal-title":"Syst Rev"},{"key":"-20240829","first-page":"Ed000142","article-title":"Updated guidance for trusted systematic reviews: a new edition of the cochrane handbook for systematic reviews of interventions","volume":"10","author":"Cumpston","year":"2019","journal-title":"Cochrane Database Syst Rev"},{"key":"-20240829","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","article-title":"Bias in meta-analysis detected by a simple, graphical test","volume":"315","author":"Egger","year":"1997","journal-title":"BMJ"},{"key":"-20240829","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1159\/000474256","article-title":"Long-term urodynamic effects of finasteride in benign prostatic hyperplasia: a pilot study","volume":"24","author":"Kirby","year":"1993","journal-title":"Eur Urol"},{"key":"-20240829","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1016\/0149-2918(95)80073-5","article-title":"Efficacy, tolerability, and effect on health-related quality of life of finasteride versus placebo in men with symptomatic benign prostatic hyperplasia: a community based study","volume":"17","author":"Byrnes","year":"1995","journal-title":"Clinl Ther"},{"key":"-20240829","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1056\/NEJM199608223350801","article-title":"The efficacy of terazosin, finasteride, or both in benign prostatic hyperplasia.Veterans Affairs Cooperative Studies Benign Prostatic Hyperplasia Study Group","volume":"335","author":"Lepor","year":"1996","journal-title":"New Engl J Med"},{"key":"-20240829","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1016\/S0090-4295(98)00094-6","article-title":"Long-term effects of finasteride in patients with benign prostatic hyperplasia: a double-blind, placebo-controlled, multicenter study.PROWESS Study Group","volume":"51","author":"Marberger","year":"1998","journal-title":"Urology"},{"key":"-20240829","first-page":"1251","article-title":"Efficacy and safety of finasteride therapy for benign prostatic hyperplasia: results of a 2-year randomized controlled trial (the PROSPECT study).Proscar Safety Plus Efficacy Canadian Two year Study","volume":"155","author":"Nickel","year":"1996","journal-title":"CMAJ"},{"key":"-20240829","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/S0149-2918(97)80113-0","article-title":"Efficacy and tolerability of finasteride in symptomatic benign prostatic hyperplasia: a primary care study. Primary Care Investigator Study Group","volume":"19","author":"Tenover","year":"1997","journal-title":"Clinl Ther"},{"key":"-20240829","doi-asserted-by":"crossref","first-page":"1825","DOI":"10.1016\/j.juro.2015.11.065","article-title":"Time course of incident adverse experiences associated with doxazosin, finasteride and combination therapy in men with benign prostatic hyperplasia: the MTOPS trial","volume":"195","author":"Kaplan","year":"2016","journal-title":"J Urol"},{"key":"-20240829","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1056\/NEJM199802263380901","article-title":"The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia. Finasteride Long-Term Efficacy and Safety Study Group","volume":"338","author":"McConnell","year":"1998","journal-title":"New Engl J Med"},{"key":"-20240829","first-page":"37","article-title":"Therapeutic effects of finasteride in benign prostatic hyperplasia: a randomized double-blind controlled trial","volume":"94","author":"Yu","year":"1995","journal-title":"J Formos Med Assoc"},{"key":"-20240829","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1016\/S0190-9622(98)70007-6","article-title":"Finasteride in the treatment of men with androgenetic alopecia. Finasteride Male Pattern Hair Loss Study Group","volume":"39","author":"Kaufman","year":"1998","journal-title":"J Am Acad Dermatol"},{"key":"-20240829","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1016\/S0190-9622(99)70081-2","article-title":"Finasteride in the treatment of men with frontal male pattern hair loss","volume":"40","author":"Leyden","year":"1999","journal-title":"J Am Acad Dermatol"},{"key":"-20240829","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1046\/j.1365-2133.2000.03780.x","article-title":"Finasteride increases anagen hair in men with androgenetic alopecia","volume":"143","author":"Van Neste","year":"2000","journal-title":"Br J Dermatol"},{"key":"-20240829","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1097\/00042728-200510000-00002","article-title":"Effects of finasteride (1 mg) on hair transplant","volume":"31","author":"Leavitt","year":"2005","journal-title":"Dermatol Surg"},{"key":"-20240829","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1067\/mjd.2002.120537","article-title":"Changes in hair weight and hair count in men with androgenetic alopecia after treatment with finasteride, 1 mg, daily","volume":"46","author":"Price","year":"2002","journal-title":"J Am Acad Dermatol"},{"key":"-20240829","first-page":"247","article-title":"Finasteride in the treatment of Japanese men with male pattern hair loss","volume":"14","author":"Kawashima","year":"2004","journal-title":"Eur J Dermatol"},{"key":"-20240829","first-page":"150","article-title":"Efficacy and tolerability of finasteride 1 mg in men aged 41 to 60 years with male pattern hair loss","volume":"13","author":"Whiting","year":"2003","journal-title":"Eur J Dermatol"},{"key":"-20240829","first-page":"252","article-title":"Efficacy, safety, and tolerability of dutasteride 0.5 mg once daily in male patients with male pattern hair loss: a randomized, double-blind, placebo-controlled, phase III study","volume":"63","author":"Eun","year":"2010","journal-title":"Clin Drug Invest"},{"key":"-20240829","doi-asserted-by":"crossref","first-page":"29","DOI":"10.2165\/11593750-000000000-00000","article-title":"Efficacy and safety of dutasteride in Chinese adults with symptomatic benign prostatic hyperplasia: a randomized, double-blind, parallel-group, placebo-controlled study with an open-label extension","volume":"32","author":"Na","year":"2012","journal-title":"Clin Drug Invest"},{"key":"-20240829","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1016\/S0090-4295(02)01905-2","article-title":"Efficacy and safety of a dual inhibitor of 5-alpha-reductase types 1 and 2 (dutasteride) in men with benign prostatic hyperplasia","volume":"60","author":"Roehrborn","year":"2002","journal-title":"Urology"},{"key":"-20240829","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1111\/j.1473-2165.2007.00297.x","article-title":"Dutasteride improves male pattern hair loss in a randomized study in identical twins","volume":"6","author":"Stough","year":"2007","journal-title":"J Cosmet Dermatol"},{"key":"-20240829","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1111\/j.1442-2042.2009.02357.x","article-title":"Efficacy and safety of dutasteride in Japanese men with benign prostatic hyperplasia","volume":"16","author":"Tsukamoto","year":"2009","journal-title":"Int J Urol"},{"key":"-20240829","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1111\/1346-8138.14329","article-title":"Prospective randomized study of sexual function in men taking dutasteride for the treatment of androgenetic alopecia","volume":"45","author":"Tsai","year":"2018","journal-title":"J Dermatol"},{"key":"-20240829","first-page":"550","article-title":"The effects of finasteride on scalp skin and serum androgen levels in men with androgenetic alopecia","volume":"41","author":"Drake","year":"1999","journal-title":"J Am Acad Dermatol"},{"key":"-20240829","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1056\/NEJM199210223271701","article-title":"The effect of finasteride in men with benign prostatic hyperplasia","volume":"327","author":"Gormley","year":"1992","journal-title":"New Engl J Med"},{"key":"-20240829","first-page":"555","article-title":"Clinical dose ranging studies with finasteride, a type 2 5alpha-reductase inhibitor, in men with male pattern hair loss","volume":"41","author":"Roberts","year":"1999","journal-title":"J Am Acad Dermatol"},{"key":"-20240829","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1002\/pros.2990220403","article-title":"Finasteride (MK-906) in the treatment of benign prostatic hyperplasia","volume":"22","year":"1993","journal-title":"Prostate"},{"key":"-20240829","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1016\/j.jaad.2006.05.007","article-title":"The importance of dual 5alpha-reductase inhibition in the treatment of male pattern hair loss: results of a randomized placebo-controlled study of dutasteride versus finasteride","volume":"55","author":"Olsen","year":"2006","journal-title":"J Am Acad Dermatol"},{"key":"-20240829","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/j.jaad.2013.10.049","article-title":"A randomized, active- and placebo-controlled study of the efficacy and safety of different doses of dutasteride versus placebo and finasteride in the treatment of male subjects with androgenetic alopecia","volume":"70","author":"Gubelin Harcha","year":"2014","journal-title":"J Am Acad Dermatol"},{"key":"-20240829","doi-asserted-by":"crossref","first-page":"1220","DOI":"10.4088\/JCP.12m07887","article-title":"Depressive symptoms and suicidal thoughts among former users of finasteride with persistent sexual side effects","volume":"73","author":"Irwig","year":"2012","journal-title":"J Clin Psychiatry"},{"key":"-20240829","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/1472-6904-6-7","article-title":"Finasteride induced depression: a prospective study","volume":"6","author":"Rahimi-Ardabili","year":"2006","journal-title":"BMC Clin Pharmacol"},{"key":"-20240829","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1210\/jcem-70-4-1136","article-title":"Effects of finasteride (MK-906), a 5 alpha-reductase inhibitor, on circulating androgens in male volunteers","volume":"70","author":"Gormley","year":"1990","journal-title":"J Clin Endocrinol Metab"},{"key":"-20240829","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1016\/j.jsxm.2016.07.006","article-title":"Effect of 5\u03b1-reductase inhibitors on sexual function: a meta-analysis and systematic review of randomized controlled trials","volume":"13","author":"Liu","year":"2016","journal-title":"J Sex Med"},{"key":"-20240829","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/j.sxmr.2018.07.003","article-title":"Sexual problems of men with androgenic alopecia treated with 5-alpha reductase inhibitors","volume":"7","author":"Coskuner","year":"2019","journal-title":"Sex Med Rev"},{"key":"-20240829","first-page":"12","article-title":"Adverse sexual effects of treatment with finasteride or dutasteride for male androgenetic alopecia: a systematic review and meta-analysis","volume":"99","author":"Lee","year":"2019","journal-title":"Acta Derm Venereol"},{"key":"-20240829","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1159\/000450617","article-title":"Investigation of the plausibility of 5-alpha-reductase inhibitor syndrome","volume":"2","author":"Fertig","year":"2017","journal-title":"Skin Appendage Disord"},{"key":"-20240829","doi-asserted-by":"crossref","first-page":"1708","DOI":"10.1111\/j.1743-6109.2007.00563.x","article-title":"Finasteride 5 mg and sexual side effects: how many of these are related to a nocebo phenomenon?","volume":"4","author":"Mondaini","year":"2007","journal-title":"J Sex Med"},{"key":"-20240829","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1016\/j.juro.2013.09.059","article-title":"Efficacy and safety of the coadministration of tadalafil once daily with finasteride for 6 months in men with lower urinary tract symptoms and prostatic enlargement secondary to benign prostatic hyperplasia","volume":"191","author":"Casab\u00e9","year":"2014","journal-title":"J Urol"},{"key":"-20240829","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1159\/000497362","article-title":"Post-finasteride syndrome: an induced delusional disorder with the potential of a mass psychogenic illness?","volume":"5","author":"Trueb","year":"2019","journal-title":"Skin Appendage Disord"}],"container-title":["Asian Journal of Andrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/aja202171","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T19:11:21Z","timestamp":1787166681000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/aja202171"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10,29]]},"references-count":45,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.4103\/aja202171","relation":{},"ISSN":["1008-682X","1745-7262"],"issn-type":[{"value":"1008-682X","type":"print"},{"value":"1745-7262","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,10,29]]},"assertion":[{"value":"2020-12-18","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-09-02","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}